To Get more Insights,  Request A Free Sample 

Market Dynamics 

Drivers

Aging Population and Rising Prevalence of Chronic Diseases

One of the primary drivers of the bioelectric medicine market is the rapidly aging global population coupled with the increasing prevalence of chronic diseases. The World Health Organization (WHO) reports that by 2050, over 2 billion people worldwide will be aged 60 and over, up from 900 million in 2015. Furthermore, chronic diseases, which are often more prevalent among the elderly, account for approximately 71% of all deaths globally, according to the WHO. Bioelectric medicine offers non-invasive treatment options for chronic diseases such as diabetes, cardiac disorders, and neurological diseases, making it an attractive solution to address the growing needs of this demographic.

Rapid Technological Advancements and R&D Investments

The bioelectric medicine market is also driven by technological advancements and significant investments in research and development (R&D). The global R&D expenditure in the biotechnology sector, including bioelectric medicine, reached approximately $1.7 trillion in 2021, according to the Global Innovation Index. Advancements in bioelectronic devices, including miniaturization, improved battery life, and more precise targeting of electrical impulses, have expanded their potential applications, further driving market growth. For instance, deep brain stimulation devices have seen technological improvements that have broadened their usage in treating conditions such as Parkinson's disease, dystonia, and obsessive-compulsive disorder.

Challenge: Market Players Facing Regulatory Hurdles to Get the Approvals 

Bioelectric medicine's growth challenges traditional regulatory frameworks, demanding novel, comprehensive structures addressing unique safety, efficacy, and clinical trial considerations. Corporations must forge proactive partnerships with regulatory bodies to navigate these complexities. Developing these regulatory frameworks requires thorough research and collaboration among industry and healthcare stakeholders. Obtaining regulatory approval in the global bioelectric medicine market involves multiple stages, from preclinical testing to comprehensive evaluations of safety and effectiveness. However, the time-consuming process and significant financial commitments, particularly daunting for smaller firms, can delay market entry of new bioelectric therapies and devices, impacting market dynamics and competitiveness.

Segmental Analysis 

By Type 

As per the latest market analysis, the healthcare sector is witnessing a significant growth shift towards implantable bioelectric medicine, accounting for over 95% of the total revenue. These sophisticated medical interventions, highly dependent on electrical signals to manage and treat diseases, are steadily transforming the global healthcare landscape. From pain management to cardiac arrhythmia, bioelectric medicine continues to pioneer innovations, paving the way for a new era in medical science.

Of particular interest within this highly promising segment is the pacemaker industry, contributing more than 36% to the total revenue. The pacemaker, an implantable bioelectric device, is crucial in the management of life-threatening heart conditions. These devices ensure the optimal functioning of the heart by delivering electric pulses to correct irregular heart rhythms, improving both the quality and longevity of patient life.

This dominance of the pacemaker segment could be attributed to several factors, including an aging global population, a rise in cardiovascular diseases, advancements in technology, and increased accessibility to such medical interventions. The trend also reflects the effectiveness and acceptance of such devices by medical practitioners and patients alike.

 To Understand More About this Research:  Request A Free Sample 

By Application

The global bioelectric medicine market has been experiencing significant growth, with a particular focus on cardiovascular applications. In fact, the segment is projected to keep holding its dominance over the forecast period. The dominance of cardiovascular disorders in the global bioelectric medicine market can be attributed to the high prevalence of these conditions, the potential for targeted neuromodulation therapies, and the growing recognition of bioelectric medicine as a viable treatment approach. The combination of clinical evidence, market growth, and industry interest underscores the significance of bioelectric medicine in addressing the global burden of cardiovascular disorders. 

Cardiovascular disorders, including heart diseases and related conditions, are the leading cause of morbidity and mortality worldwide. According to the World Health Organization (WHO), cardiovascular diseases account for approximately 17.9 million deaths annually, representing 31% of all global deaths. The economic burden of cardiovascular diseases is substantial, with healthcare costs and productivity losses reaching billions of dollars globally each year.

Regional Analysis

North America is positioned to dominate the global bioelectric medicine market, accounting for over 44% of the market revenue during the forecast period. The region is expected to experience a significant compound annual growth rate (CAGR) of 5.96%. This regional dominance can be attributed to several key factors.

North America, particularly the United States, possesses a highly advanced healthcare infrastructure. In 2020, the United States allocated nearly $4 trillion towards healthcare expenditure, which accounted for approximately 18% of the country's GDP, as reported by the Centers for Medicare & Medicaid Services. This substantial investment in healthcare infrastructure contributes to the widespread adoption of innovative technologies, including bioelectric medicine.

North America boasts the presence of key market players in the bioelectric medicine industry, such as Medtronic, Boston Scientific Corporation, and Nevro Corp. These influential companies play a pivotal role in driving research and development activities, resulting in continuous technological advancements and overall market growth.

Moreover, the high prevalence of chronic diseases in North America further fuels the region's dominance in the bioelectric medicine market. According to the Centers for Disease Control and Prevention (CDC), six out of ten adults in the United States suffer from at least one chronic disease, with four out of ten adults experiencing two or more chronic conditions. As bioelectric medicine offers effective treatments for a wide range of chronic ailments, the significant prevalence of such diseases creates substantial demand in the market.

The favorable reimbursement policies in the United States contribute to the widespread adoption of bioelectric medicine. The country possesses a well-established insurance system that often covers innovative treatments, including bioelectric medicine. This supportive reimbursement environment creates a conducive atmosphere for healthcare providers and patients to embrace these advanced therapeutic solutions.

Recent Developments:

• September 2022: Pulse Biosciences announced a strategic shift towards exploring additional opportunities for medicinal applications of nano-pulse stimulation (NPS). The company plans to advance their core NPS™ technology in cardiac and oncology sectors, with plans for expansion into areas such as oncology, gastroenterology, and other sectors.
• March 2021: Medtronic Inc. received US FDA approval for its Intellis Platform equipped with Differential Target Multiplexed (DTM) programming. This device is designed to treat chronic intractable back and leg pain.
• January 2021: Boston Scientific received FDA approval for its Vercise Deep Brain Stimulation (DBS) Systems. This product is designed to assist patients diagnosed with essential tremor or parkinsonian tremor that cannot be effectively controlled with medication alone.
• July 2021: Merck KGaA, based in Darmstadt, Germany, partnered with Innervia Bioelectronics to develop graphene-based bioelectronic treatments for the vagus nerve, aimed at severe chronic diseases. The collaboration aims to leverage the expertise of both companies to improve therapies for diseases with unmet medical requirements within the treatment areas addressed by Merck.
• February 2021: Pulse Biosciences, Inc. announced that the first clinical patients have been treated with the CellFX System. This marked the first commercial use of the CellFX System and was part of the company's deliberate launch program. Product shipments were sent to respected leaders in dermatology in Europe and the United States.

Key Players in the Global Bioelectric Medicine Market

• Abbott Laboratories
• Boston Scientific Corporation
• Biotronik SE & Co. KG
• Cochlear Limited
• ElectroCore Inc.
• Inspire Medical Systems, Inc.
• LivaNova Plc.
• Medtronic Plc.
• MED-EL
• Nevro Corp.
• Nuvectra Corporation
• NeuroMetrix, Inc.
• Omron Corporation
• Pixium Vision
• Second Sight Medical Products, Inc.
• Setpoint Medical
• Stimwave LLC.
• Other Prominent Players

Market Segmentation Overview:

By Type

• Implantable Bioelectric Medicine
  • Cardiac Pacemaker
  • Implantable Cardioverter Defibrillator (ICD)
  • Spinal Cord Stimulation Device
  • Deep Brain Stimulation Device
  • Cochlear Implant
  • Vagus Nerve Stimulation Device
  • Retinal Implant
  • Others
• Non-Implantable Bioelectric Medicine

By Application

• Chronic Pain Management
• Cardiovascular Disorder
• Hearing Disorder
• Others

By End Users

• Hospitals
• Ambulatory Surgical centers
• Research Institutes
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America